Quick answer: “GLP-3” is not the established receptor name for retatrutide’s third target. Published pharmacology describes retatrutide as an agonist of the GIP, GLP-1, and glucagon receptors. The “GLP-3” phrase appears in online searches and informal labels, but it can blur the distinction between a drug’s target and a hormone or receptor name.
People searching “what is GLP-3?” may be trying to understand retatrutide, sometimes informally nicknamed a “GLP-3” medicine. The clearer scientific description is a triple receptor agonist. This article explains the terms without treating a search phrase as a formal drug class.
Is GLP-3 an established name for retatrutide?
No. The peer-reviewed Phase 2 trial describes retatrutide as acting at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. The article does not identify a “GLP-3 receptor” as the molecule’s third target. The phrase “GLP-3” is therefore not a precise substitute for the published receptor names.
Why the phrase appears online
Informal shorthand can make a multi-target medicine sound like a new numbered member of a GLP series. But names that look similar are not necessarily synonyms. In scientific writing, use the target actually studied and specify whether “GLP-3” is an informal search phrase rather than an official receptor classification.
What are retatrutide’s reported receptor targets?
Retatrutide is a single peptide designed to activate three receptors: GIP, GLP-1, and glucagon. The Phase 2 publication and pharmacology literature use these target names. Calling it a “triple agonist” summarizes the three targets; it does not establish that each target contributes equally or that the molecule has a particular clinical advantage.
GLP-1 receptor
The GLP-1 receptor is one of the targets described for retatrutide and for other medicines in this field. GLP-1 is a hormone name; GLP-1 receptor is the corresponding receptor name. Keeping ligand and receptor terminology distinct avoids treating the medicine as the hormone itself.
GIP receptor
GIP stands for glucose-dependent insulinotropic polypeptide. The GIP receptor is a separate target from the GLP-1 receptor, even though medicines may be designed to engage both.
Glucagon receptor
The glucagon receptor is the third target named in retatrutide’s published pharmacology. It is not called the “GLP-3 receptor” in the formal nomenclature summarized by the IUPHAR/BPS Guide to Pharmacology.
How is GLP-3 different from GLP-1 and GLP-2?
GLP-1 and GLP-2 are established glucagon-related peptide hormone names with their own receptor terminology. “GLP-3,” in contrast, is not the accepted receptor label for glucagon in the pharmacology sources cited here. Similar numbering can prompt confusion, so a careful article should write “glucagon receptor” when discussing retatrutide’s third target.
Check the full term, not just the abbreviation
When a page says “GLP-3,” ask whether it means a formal hormone, a receptor, a nickname, or a search keyword. Then check the paper’s actual terminology. Precise naming is especially important when comparing molecules, interpreting a clinical trial, or distinguishing research terminology from product marketing.
Does the “GLP-3” label prove a clinical effect?
No. A label is not clinical evidence. Whether retatrutide changes a study outcome must be evaluated from the relevant clinical trial: its participants, protocol, comparator, endpoints, follow-up, and reported safety information. Receptor pharmacology can support a biological rationale, but it cannot replace outcome data.
Likewise, “three receptors” is not by itself proof of superior efficacy, safety, or suitability. As of October 10, 2026, retatrutide remains investigational in the United States. This explainer is not a treatment or product-use guide.
How to write about GLP-3 and retatrutide accurately
- Use “GIP, GLP-1, and glucagon receptor agonist” for the reported retatrutide target profile.
- If discussing “GLP-3,” identify it as an informal search term and clarify that it is not the established name for the glucagon receptor.
- Link claims about pharmacology to a peer-reviewed source or authoritative pharmacology database.
- Keep mechanism statements separate from claims about clinical outcomes or regulatory status.
GLP-3 and retatrutide FAQs
Is retatrutide a GLP-3 agonist?
Published sources describe it as an agonist at GIP, GLP-1, and glucagon receptors. “GLP-3 agonist” is not the precise target description used in those sources.
What does GLP-3 mean in online retatrutide discussions?
It is commonly used as informal shorthand or a search phrase. Check the context; it should not be mistaken for the published glucagon-receptor name.
What is retatrutide’s third receptor target?
The glucagon receptor, often abbreviated GCG receptor.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. doi:10.1056/NEJMoa2301972.
- IUPHAR/BPS Guide to Pharmacology. Glucagon family of receptors, version 2025.3. GtoPdb CITE. Accessed October 10, 2026.
- U.S. FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Accessed October 10, 2026.
Editorial note: This is a terminology and research-literacy article. It is not medical advice or an endorsement. Reviewed October 10, 2026.
